DelMar Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board (SAB). Its inaugural members are Drs. Napoleone Ferrara and John de Groot. Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, is an expert in glioma biology and angiogenesis, which is the key area of clinical development for VAL-083, the Company's lead asset. Dr. Ferrara is a world-renowned molecular biologist whose pioneering work on the identification of VEGF led to the development of Avastin, Roche's multibillion dollar cancer agent indicated for the treatment of GBM as well as numerous other solid tumors. Dr. Ferrara will continue his role as a member of DelMar's Board of Directors and serve as the SAB's Chairman.